Neimeth Cuts Share Premium to N390m, Moves N1.99bn to Retained Earnings

Shareholders of Neimeth International Pharmaceuticals Plc have approved a capital restructuring scheme that will reduce the company’s share premium account from N2.38 billion to N390.02 million and transfer N1.99 billion into retained earnings reserves.

The approval was granted at a Court-Ordered Meeting held virtually, where shareholders endorsed the Scheme of Arrangement designed to strengthen the pharmaceutical company’s balance sheet and improve financial flexibility.

The restructuring forms part of the company’s broader corporate reorganisation efforts aimed at repositioning the business for long-term growth and improving its capital structure.

According to details contained in the Scheme Document dated February 25, 2026, the company will reduce its share premium account by N1.99 billion while transferring the same amount into retained earnings, also referred to as revenue reserves.

Share premium represents funds paid by investors above the nominal value of a company’s shares and forms part of shareholders’ equity. However, such funds are subject to regulatory restrictions and are not freely available for dividend payments or certain operational adjustments.

Retained earnings, on the other hand, provide companies with greater flexibility as they can be used to offset accumulated losses, strengthen reserves, support future dividend declarations, or finance other balance sheet adjustments.

Industry analysts described the move as a balance sheet restructuring exercise intended to optimise the company’s equity structure without altering total shareholders’ funds.

The restructuring does not involve the injection of fresh capital into the business and is not expected to have an immediate impact on the company’s cash flow position or earnings performance.

Instead, the exercise represents an internal reclassification of equity aimed at unlocking trapped reserves within the company’s balance sheet and improving financial presentation.

Analysts noted that the transfer of N1.99 billion into retained earnings could improve the company’s financial flexibility and enhance investor perception of its overall financial health.

The restructuring is also expected to create room for possible future dividend declarations if the company returns to sustained profitability.

Financial experts further stated that the move may improve the company’s attractiveness to lenders and potential investors by strengthening its reserve structure and enhancing its balance sheet position.

The shareholders also authorised the Board of Directors to implement the Scheme of Arrangement in full and approve any modifications that may be required by the Securities and Exchange Commission or the court.

In addition, the company’s solicitors were mandated to seek court sanction for the scheme and obtain all necessary incidental orders required to give legal effect to the restructuring exercise.

The approval marks another strategic step by the pharmaceutical company as it seeks to reposition operations amid increasing competition and rising operational costs within Nigeria’s healthcare and pharmaceutical sector.

The company has continued to focus on operational efficiency, regulatory compliance and long-term sustainability as part of efforts to strengthen market positioning and support future expansion plans.

Market observers noted that corporate restructuring exercises such as the Neimeth arrangement are becoming increasingly common among listed companies seeking to improve balance sheet efficiency and strengthen shareholder value amid challenging economic conditions.

The development also reflects growing efforts by Nigerian firms to optimise capital structures and enhance operational resilience in response to inflationary pressures, foreign exchange volatility and evolving regulatory requirements.

With the approval secured from shareholders, the company is expected to proceed with regulatory and court processes required to complete the restructuring and fully implement the approved scheme.